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Significance Statement 
The baculovirus expression vector system (BEVS) is widely used for recombinant protein 
production throughout the world. The system is based on gene expression in virus-infected 
insect cells that have the capability to recognise and process translational modification sites, 
allowing the formation of authentic eukaryotic proteins. The BEVS offers other advantages 
such as inherent safety, scalability and speed. These features combined have led to wide-
spread use including production of vaccine targets in both human and veterinary medicine. 
Words = 76 
ABSTRACT 
This chapter provides information on the replication cycle of insect baculovirus to provide an 
understanding of how this virus has been adapted for use as an expression vector for 
recombinant proteins in insect cells. We provide an overview of the virus structure and its 
unique bi-phasic replication cycle that has been exploited in developing the virus as an 
expression vector. We also review the development of the baculovirus expression vector 
system (BEVS) since the mid 1980’s to the present day in which the BEVS is now an 
established tool for the production of a range of recombinant proteins and multi-protein 
complexes including virus-like particles. We describe advances made to the BEVS to allow 
the rapid and easy production of recombinant viruses and developments to improve protein 
yield. We finish by describing the application of recombinant BacMam as vectors for the 
delivery of genes into mammalian and human cells.  
 
Word count = 148 
Keywords: Baculovirus expression vector, BEVS, BacMam, insect cells 
 
INTRODUCTION 
Baculoviruses are arthropod-specific viruses that belong to the family Baculoviridae and 
infect more than 600 host species found in a number of different orders (reviewed by 
Herniou et al., 2003; Possee et al., 2010). In nature, baculoviruses play a key role in 
regulating insect populations and so have successfully been used as pesticides due to their 
host specificity and safety for the environment and human health (reviewed by Bonning & 
Hammock, 1992; van Beek & Davis, 2016).  
An increase in the biological understanding of the prototype baculovirus, Autographa 
californica multiple nucleopolyhedrovirus (AcMNPV), lead to the application of 
baculoviruses as an expression system in the mid 1980’s (Smith et al., 1983a). Since then the 
baculovirus expression vector system (BEVS) has been used to express thousands of 
recombinant targets and some of these have been utilized for the generation of 
commercially available vaccines (reviewed by Felberbaum, 2015). The BEVS proved highly 
suitable for recombinant protein production due to the high level of gene expression driven 
from a very late gene promoter, the polyhedron gene promoter, in virus-infected insect 
cells.  
The insect cells used in the BEVS have the capability to recognise and process signal 
peptides, support oligomerisation and undertake post-translational modifications such as 
glycosylation, acylation, phosphorylation and disulphide bond formation, enabling the 
correct formation of authentic eukaryotic proteins; in contrast to prokaryotic expression 
systems (Geisler & Jarvis, 2009; Klenk, 1996). Another advantage of the BEVS is that the 
insect cells grow in serum-free media and can easily be scaled up in shaking cultures or 
bioreactors at 27-28°C.  
This unit describes the variety of different BEVS and their advantages and disadvantages; 
protocols for using the different systems can be obtained from the appropriate suppliers. 
However, protocols related to the generation of baculovirus vectors using the homologous 
recombination method will be discussed further in UNIT 5.5, along with more general 
protocols for expression optimisation and large scale production.  
 
 
BACULOVIRUS LIFE CYCLE 
The common rod-shaped nucleocapsid of baculoviruses varies between 200-400 nm in 
length, is about 36 nm wide and encloses a double-stranded, circular supercoiled DNA 
genome, which is between 80-180 kbp in size (Funk et al., 1997). The prototype AcMNPV, 
which forms the basis of most expression vectors, was the first baculovirus to be sequenced 
completely and was found to be 134kbp in size and harbours 154 ORFs (Ayres et al., 1994).  
Baculoviruses have a bi-phasic replication cycle, which is driven by the two structurally 
distinct forms of the virus; budded virus (BV) and the occlusion-derived virus (ODV). Primary 
infection and horizontal transmission of baculovirus in host larvae is mediated by the oral 
route using ODV, after ingestion of occlusion bodies (OBs) (Figure 5.4.1). Secondary infection 
involving the spread of infection from tissue to tissue within the host larvae is initiated by 
the BV form (reviewed by Possee et al., 2010). Budded virus is also the form that is used in 
cell culture for the BEVS, as it has been shown to be about 1,800-fold more infectious than 
ODV (Volkman et al., 1976). Virus gene expression, DNA replication and the synthesis of 
structural proteins occurs during four successive phases: immediate-early, delayed-early, 
late and very late (reviewed by Slack & Arif, 2007). New progeny virus form in the nucleus 
and in the earlier stages of infection, nucleocapsids leave the nucleus to migrate through 
the cytoplasm to the plasma membrane to form BV, whereas in the very late stages, they 
remain in the nucleus and become occluded as ODV (reviewed by Slack & Arif, 2007).  
The BV obtains its envelope when the nucleocapsids bud through the cell plasma 
membrane. The major envelope protein that is required for BV attachment, fusion and 
budding is acquired during the budding stage, and for AcMNPV this protein is GP64 
(reviewed by Slack & Arif, 2007). Nucleocapsids destined to become ODV remain in the 
nucleus and gain an envelope by an unknown process that may be de novo synthesis or 
from the nuclear membrane. The ODV become occluded in large proteinaceous OBs, which 
in the case of AcMNPV is formed from polyhedrin protein, which is expressed to very high 
levels in the very late stage of infection. The OBs allow the ODV to remain viable in the 
environment until a susceptible host is present, which can be several seasons. For a more 
comprehensive review of baculovirus life cycle, see Possee et al. (2010) or Slack and Arif 
(2007). 
The polyhedrin gene along with the other highly expressed very late gene, p10, both 
produce proteins that are only required for horizontal transmission and not for systemic 
infection within the larva or for the spread of infection in insect cell culture; these proteins 
are, therefore, not essential for BV production (Smith et al., 1983b; Summers, 2006; Vlak et 
al., 1988). Therefore, the polyhedrin or p10 gene coding regions can be replaced by 
recombinant genes, retaining the very strong promoters to drive foreign gene expression. 
 
BACULOVIRUS EXPRESSION SYSTEM 
Human β-interferon was the first protein successfully produced to high levels using 
baculovirus vectors, when its gene coding region was inserted in place of the polyhedron 
gene (polh) coding region in the AcMNPV genome (Smith et al., 1983a). There have been 
several advances in the BEVS since the mid 1980's, which are explained in the following 
sections. Due to the large size of the baculovirus genome, it is difficult to insert genes 
directly into the virus genome using molecular cloning techniques, although there is one 
commercial system that uses this approach (BaculoDirectTM, Thermo Fisher Scientific Inc). 
Most baculovirus expression systems involve the use of an intermediate plasmid vector into 
which the foreign gene is cloned, and then various methods have been developed to 
transfer the gene from the plasmid vector into the virus genome, as described below 
(reviewed by King et al., 2007).  
Homologous recombination in insect cells 
The expression systems classified in this section produce recombinant baculovirus in insect 
cells by homologous recombination between the baculovirus genome and the transfer 
plasmid containing the gene of interest, which is normally under of the control of the polh 
promoter. However, alterative transfer plasmids exist that contain other insect promoters 
(p10, p6.9) and those that allow simultaneous expression of two target genes (Weyer & 
Possee, 1991) or more (Belyaev & Roy, 1993). To facilitate recombination, the gene of 
interest in the transfer vector is flanked by fragments of the baculovirus genome identical to 
the sequences up and downstream of the desired insertion site, generally the polh locus.  
The original recombinant baculoviruses were produced by homologous recombination 
between the intact, circular AcMNPV genome and a transfer vector and resulted in the 
production of recombinant, polyhedrin-negative viruses. However, because homologous 
recombination occurs at very low frequency, only small numbers of recombinant viruses 
were generated in a background of polyhedrin-positive (parental) viruses. The polyhedrin-
negative viruses had to be isolated via several rounds of tedious plaque purification in which 
virus-infected cells containing a polyhedra-negative phenotype were identified by light 
microscopy (King & Possee, 1992; Smith et al., 1983a).  
This original method was first improved by linearizing the AcMNPV genome at the insertion 
site (polh locus) before the homologous recombination step. This resulted in a greater 
recovery of recombinant viruses (~30%) because linearised virus DNA cannot replicate and 
produce infectious virus (Kitts et al., 1990). The system was improved further by the 
generation of a triple Bsu361-disgested AcMNPV genome that contained lacZ at the polh 
locus, which was termed BacPAK6 (Kitts & Possee, 1993). The triple-digested and linearized 
BacPAK6 DNA lacked a functional orf1629 that is essential for BV production; this gene is 
restored after homologous recombination with the transfer plasmid that contains orf1629 in 
the flanking sequences. This development greatly decreased the parental virus background, 
improving the efficiency of recombinant virus production up to 90% and reduced the 
number of plaque purification rounds required to isolate a recombinant virus. Replacement 
of the native polh coding sequence with that of lacZ also enabled plaques containing 
recombinant virus to be identified by blue-white selection, with parental non-recombinant 
virus plaques turning blue in the presence of X-gal (Kitts & Possee, 1993). The BacPAK6 
system formed the basis of a number of commercial baculovirus systems in the 1990s and is 
currently available from Oxford Expression Technologies (OET, www. oetltd.com). 
A new platform technology that built on the BacPAK6 system has been developed that 
allows a rapid one-step generation of recombinant viruses, and which is therefore suitable 
for high throughput production (Possee et al., 2008). This platform is based on maintaining 
an AcMNPV genome that contains only part of orf1629 in E. coli, due to the insertion of a 
bacterial artificial chromosome (BAC) at the polh locus. Therefore, this removes the 
requirement for DNA linearization prior to the homologous recombination step in insect 
cells and results in 100% recovery of recombinant virus. There is therefore no need for time-
consuming plaque-purification steps, reducing the time and complexity of making 
recombinant baculoviruses. The system has been commercialised as the flashBAC™ system 
(Possee et al., 2008) by OET Ltd 
The yield and quality of recombinant protein has been improved by making non-essential 
gene deletions in the virus genomes that are used in the flashBAC™ system. This has 
resulted in the two new categories of expression vector namely flashBACGOLD™ (FBG; in 
which chitinase and cathepsin have been deleted) (Hitchman et al., 2010b) and 
flashBACULTRA™ (FBU; in which chitinase, cathepsin, p26, p10 and p74 have been deleted) 
(Hitchman et al., 2010a). Deletion of chitinase, which is targeted to and partially blocks the 
endoplasmic reticulum in infected cells, results in improved yields of membrane-targeted or 
secreted proteins (Hitchman et al., 2010b). Deletion of cathepsin improves the yield of 
proteins that might otherwise be degraded by this viral proteinase (Hitchman et al., 2010b).  
 
Site-directed transposition in Escherichia coli 
A major improvement, to avoid the work involved in the isolation of recombinant viruses by 
plaque purification, was the generation of an AcMNPV bacmid that can be amplified and 
modified in E.coli but also is infectious in insect cells (Luckow et al., 1993). This bacmid 
contains lacZ as a selection marker and Tn7 transposition sites. The other major element of 
this system is a transfer vector that contains the gene of interest flanked by Tn7 
transposition sites. When the transfer vector is introduced into E.coli containing the 
AcMNPV bacmid, a site-directed transposition occurs between the bacmid genome and the 
transfer vector, inserting the gene of interest into the polh locus disrupting the lacZ 
sequence. Once the recombinant bacmid is identified, based on antibiotic resistance and 
blue/white selection on agar plates, it is amplified, isolated and introduced into insect cells 
for BV production (Luckow et al., 1993). Although this system removes the requirement of 
plaque-purification, there are still several steps necessary in E. coli before recombinant 
viruses can be generated in insect cells. This system has been designated as Bac-to-Bac® and 
is commercially available from Thermo Fisher Scientific Inc.  
 
A second baculovirus expression system using a similar technique of Tn7 transposition in E. 
coli has been designed to allow the production of multiprotein complexes. This system 
allows the production of a recombinant baculovirus that can contain multiple target genes 
that are under the control of either the p10 or polh promoters. Each gene of interest 
requires cloning into a transfer vector using standard cloning techniques. The assembly of 
the multigene expression transfer vector is aided by homologous and site-specific 
recombinases. Interestingly, this system offers alternative method for construction of a 
multigene expression transfer vector that could in theory contain an unlimited number of 
target genes. This involves using standard cloning techniques that allows specific restriction 
sites to be recycled after each insertion into the transfer vector. This system is designated as 
MultiBacTM and is commercially available from Geneva Biotech (Berger et al., 2004; 
Fitzgerald et al., 2006). 
 
A potential drawback to these multi-bacmid based systems is the challenge of isolating 
recombinants from the parental bacmid, but the development of the  BVBoost system 
improved the recovery of recombinant bacmids at the selection stage by the addition of the 
negative-selection marker, sacB (Airenne et al., 2003). 
 
BacMam vectors 
The BEVS has been further developed beyond recombinant protein expression in insect cells 
and into the delivery of target genes into mammalian cells, for protein production and for 
gene therapy purposes. In this development virus vectors are refered to as BacMam and the 
recombinant baculovirus contains an expression cassette with a mammalian cell or virus 
promoter, replacing the polh or other baculovirus promoter. The recombinant BacMam 
enters mammalian cells by transduction, allowing the delivery of the expression cassette, 
but not the replication of the baculovirus as insect promoters are not active in mammalian 
cells (reviewed by Airenne et al., 2013; Kost et al., 2005). Recombinant BacMam can be 
made by any of the baculovirus technologies described above, as long as the transfer vector 
contains the appropriate promoter, which is most commonly the CMV early gene promoter. 
This approach has recently been shown to work ex vivo, where a BacMam transduction was 
successfully used to deliver a target gene to a whole porcine kidney (Hitchman et al., 2016). 
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FIGURE LEGENDS 
Figure 5.4.1 The baculovirus replication cycle  
 
Schematic representation of the Baculovirus replication cycle 
 
INGESTION: The initial infection occurs when a larva inadvertently consumes occlusion 
bodies (OBs), which travel to the larva midgut. The alkaline environment (pH 10-11) of the 
midgut causes the OBs to dissolve, releasing the occlusion-derived viruses (ODVs). ENTRY TO 
THE MIDGUT: The ODVs cross a physical barrier (peritrophic membrane) to access the 
columnar cells, where they enter through direct membrane fusion to the microvillus. The 
nucleocapsid is released into the cytosol and migrates to the nucleus to deliver the viral 
genome. This results in a cascade of gene expression where viral genes are expressed, 
structural genes are synthesized, DNA replication begins and new progeny viruses are 
assembled and released. BUDDED VIRUS: The BV production occurs after the transcription 
of late genes between six to 24 hours and is involved in spreading the infection throughout 
the larva host. The BV enter the cell through receptor mediated endocytoisis. As the 
endosome acidifies, virus and endosomal envelopes fuse, releasing nucleocapsids into the 
cytoplasm. The nucleocapsids migrate to the nucleus and release the viral genome. The virus 
replication cycle is initiated as described earlier. OCCLUSION BODIES: During the very late 
phase (18 hours onwards), nucleocapsids are retained in the nucleus, acquire envelopes to 
form ODVs, and are embedded within a crystalline matrix of polyhedrin to form OBs. Mature 
OBs are released by cell lysis and their stability in the environment allows them to persist 
until a susceptible host is once again present. 
